Biocon shines on introducing world’s first biosimilar trastuzumab 'CANMAb'

20 Jan 2014 Evaluate

Biocon is currently trading at Rs. 456.50, up by 15.00 points or 3.40% from its previous closing of Rs. 441.50 on the BSE.

The scrip opened at Rs. 445.95 and has touched a high and low of Rs. 458.75 and Rs. 445.00 respectively. So far 1,10,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 491.70 on 07-Jan-2014 and a 52 week low of Rs. 255.00 on 04-Mar-2013.

Last one week high and low of the scrip stood at Rs. 474.15 and Rs. 439.00 respectively. The current market cap of the company is Rs. 9,126.00 crore.

The promoters holding in the company stood at 60.97% while Institutions and Non-Institutions held 18.79% and 20.24% respectively.

Biocon, Asia’s premier biotechnology company, has introduced CANMAb (150 mg/ 440 mg), a biosimilar trastuzumab for the treatment of HER2-positive metastatic breast cancer in India. CANMAb, developed jointly by Biocon and Mylan under a global partnership, is the world’s first biosimilar version of Herceptin and is being introduced for the benefit of patients in India.

Breast cancer is the most prevalent cancer among Indian women ahead of cervical cancer and CANMAb will offer a high quality, more affordable option to breast cancer patients in India.

CANMAb is being manufactured at Biocon’s biologics facility in Bangalore and will be available to patients around the first week of February 2014. CANMAb will be available at about 25% discount to the current list price of the reference product in India, which is already significantly lower than its price in developed markets. In addition, CANMAb’s 150 mg formulation, priced at Rs 19,500/vial, will allow extra savings to patients as they can buy smaller quantities as per their requirement.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services.

Biocon Share Price

390.40 0.15 (0.04%)
30-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1265.95
Cipla 1491.40
Zydus Lifesciences 901.30
Lupin 2081.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×